Omzo vs IVIM Health: Clinician-Guided GLP-1 Plans Compared
Quick verdict: Omzo vs IVIM Health
Omzo and IVIM Health both provide clinician-guided compounded GLP-1 care, but they differ on pricing, program structure, third-party ratings, and branded prescription options. Early verdict: choose Omzo if you need clinician-reviewed options that may include prescriptions for branded medications; choose IVIM Health if you value third-party ratings and a lower entry price with a free-month offer.
Explore Omzo clinician-guided plans
Top differences at a glance
The comparison below focuses on the most distinctive differences supported by source material: starting price and membership offers, compounded versus branded prescription options, clinician guidance and protocols, third-party ratings and published outcomes, and regulatory notes about compounded drugs.
1. Price and introductory offers
Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as captured on its landing content. IVIM Health publicly lists semaglutide at $75/month and tirzepatide at $133/month, and advertises a limited offer: a free month membership with code GIFT75 and a no-obligation free consultation valued at $75. IVIM’s ongoing published pricing includes a month-one price progression noted in the FAQ and program details.
Claim IVIM’s free month with code GIFT75
2. Compounded drugs versus branded prescription options
Both providers offer compounded GLP-1 medications. Omzo’s platform highlights a primary Compounded Medication Program where drugs are prepared by state-licensed sterile compounding pharmacies and explicitly states these compounded drugs are not FDA-approved. Omzo also notes providers may write prescriptions for FDA-approved branded medications such as Ozempic or Wegovy, but Omzo does not sell, dispense, or ship branded medications; patients would fill prescriptions at their chosen pharmacy. IVIM Health focuses on compounded semaglutide and tirzepatide only and states compounded medications are not FDA-approved.
See Omzo medication options and clinician process
3. Clinician guidance, protocols, and satisfaction signals
Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers and patient anecdotes on personalized GLP-1 care. IVIM Health highlights a proprietary GLP-1 ID protocol and points to a 4.9-star rating on both Google and Trustpilot as a strong third-party satisfaction signal. IVIM also cites internal and published observational studies tied to its protocols but clarifies those are not randomized head-to-head trials. Both platforms note prescriptions are subject to clinician review and final provider determination.
Review IVIM’s GLP-1 ID protocol and reviews
4. Outcomes, evidence, and regulatory notes
IVIM references two peer-reviewed retrospective observational studies and a proprietary study claiming up to 40% faster results with its protocol; the company qualifies these as not head-to-head randomized trials and notes results may vary. Omzo presents user experience language and emphasizes that compounded medications offered through its program are produced in FDA-registered facilities but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Both sources clearly state compounded medications are not FDA-approved and results are not guaranteed.
Comparison table
| Criteria | Omzo | IVIM Health |
|---|---|---|
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Semaglutide $75/mo; tirzepatide $133/mo; program fees may apply |
| Intro offer | No free-month code captured | Free month membership with code GIFT75; free consultation valued at $75 |
| Medication types | Compounded program; providers may prescribe branded meds but Omzo does not dispense branded drugs | Compounded semaglutide and tirzepatide only per site content |
| Clinician guidance | Clinician-guided plans reviewed by licensed U.S. providers | Clinician-guided with proprietary GLP-1 ID titration and optimization protocol |
| Third-party validation | Not supplied in the captured content | 4.9-star rating on Google and Trustpilot cited |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA | Compounded medications are not FDA-approved and not reviewed by FDA |
How to decide: Choose based on what matters most
Both platforms require clinical evaluation and final prescribing decisions are made by licensed providers. If entry price and a low-cost first month matter most, IVIM Health’s free-month code GIFT75 and the published $75/mo starting point make it a clearer lower-cost entry. If you want a platform that includes clinician-reviewed access to compounded options plus the ability for a provider to prescribe an FDA-approved branded medication you would fill separately, Omzo documents that workflow.
Choose Omzo if…
You want clinician-guided plans that may include a provider-written prescription for branded medications and personalized, clinician-reviewed compounded programs. Omzo lists semaglutide starting at $179 and clarifies providers determine eligibility and prescription type.
Choose IVIM Health if…
You prioritize lower upfront cost and independent satisfaction signals. IVIM advertises a free month with code GIFT75, a no-obligation free consultation valued at $75, and a 4.9-star rating on both Google and Trustpilot, with ongoing pricing published on its site.
Primary keyword: Omzo vs IVIM Health